Mylan SA and Meridian Medical Technologies, a Pfizer subsidiary, have issued an urgent recall of their EpiPen injector, which is used by patients who have allergies, saying there was a defect with the device.

Used for anaphylaxis in patients, which is triggered by insect bites, or stings, and allergic reactions, the EpiPen auto injector comes in both junior and senior doses and retails at about R1,000 per device.

In an emergency situation, it could be deadly for patients to not have properly functioning devices and they could suffer serious health consequences.

Mylan SA head of strategic projects Tanya Anhaeusser said the voluntary recall was a precautionary measure to safeguard patients after incidents in the US and Asia during which two devices were reported to be faulty and the needles were unable to inject the amount of fluid that was necessary.

In both incidents, the company said, the contents of the devices were normal, but the actual devices were defective and there was a "potential default in the supplier component", hence the recall on a worldwide scale.

No Incidents in SA

Anhaeusser said the firm was conducting the recall because the South African stock had been part of the same batch in which the two faulty devices were found abroad, "but there has been no incidents or complaints made in SA so far".

The company has committed itself to replacing these devices at no additional cost to customers.

Mylan SA identified the EpiPen 0.3mg/0.3ml auto injector with batch number 36388, of which the company had stocked 1,211 units, as part of the faulty batch.

The EpiPen Junior injectors, of which the company had brought in about 500 units, with batch numbers 36093, 36178 and 36288, were also part of the global recall.

Anhaeusser said three of the four product batches were now close to expiry in May 2017, so customers who wished to return their product would be getting a fresh set of medication and devices. These usually last for a year.

The company said it would be working with a medical courier to collect faulty products from customers and replace them with well dated, functioning stock.

Pfizer’s share price has declined for the past month and is trading on the New York stock exchange at $33,88.

The company is working with the Medical Controls Council to help it carry out the recall of the devices.

Please sign in or register to comment.